Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma

Suvi-Tuuli Vilen,1 Tuula Salo,1,2,3 Timo Sorsa,1,4 and Pia Nyberg2,3

1 Biomedicum Helsinki, Institute of Dentistry, Research Laboratory, University of Helsinki, P.O. Box 63, Haartmaninkatu 8, 00014 Helsinki, Finland
2 Department of Diagnostics and Oral Medicine, Institute of Dentistry and the Oulu Center for Cell-Matrix Research, University of Oulu, P.O. Box 5281, 90014 Oulu, Finland
3 Oulu University Hospital, Oulu, Finland
4 Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland

Correspondence should be addressed to Suvi-Tuuli Vilen; suvi-tuuli.vilen@helsinki.fi

Received 5 November 2012; Accepted 10 December 2012

Academic Editors: S. Bhan, A. Chuang, and J. E. J. Lee

One hallmark of cancer is the degradation of the extracellular matrix (ECM), which is caused by proteinases. In oral cancers, matrix metalloproteinases (MMPs), especially MMP-9, are associated with this degradation. MMPs break down the ECM allowing cancer to spread; they also release various factors from their cryptic sites, including cytokines. These factors modulate cell behavior and enhance cancer progression by regulating angiogenesis, migration, proliferation, and invasion. The development of early metastases is typical for oral cancer, and increased MMP-9 expression is associated with a poor disease prognosis. However, many studies fail to relate MMP-9 expression with metastasis formation. Contrary to earlier models, recent studies show that MMP-9 plays a protective role in oral cancers. Therefore, the role of MMP-9 is complicated and may fluctuate throughout the different types and stages of oral cancers.

1. Introduction

Oral cancer is one of the ten most common cancers worldwide. Nearly 3% of all cancer cases are oral cancers; they are more common in men than in women; and two-thirds of oral cancer cases occur in developing countries [1, 2]. One important hallmark of cancer progression is the degradation of the extracellular matrix (ECM), which allows cancer cells to invade the surrounding tissue. Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that efficiently degrade the components of the ECM and basement membranes (BM). MMPs also release cytokines, chemokines, and growth factors from their proforms or their cryptic sites [3–6]. To date, at least 24 distinct MMP genes have been identified in humans. MMPs are classified according to their substrate specificities: gelatinases, collagenases, matrilysins, and stromelysins. The structures of all MMPs include an N-terminal signal peptide that directs the protein to either the plasma membrane insertion or to the secretory pathway; its prodomain confers its latency, and its catalytic domain has a zinc atom in its active site. MMPs are either anchored in the membrane or secreted, primarily as latent proforms that require activation before becoming catalytically competent [7–9]. Two different soluble gelatinases have been identified: gelatinase A, 72 kDa (MMP-2), and gelatinase B, 92 kDa (MMP-9). Both contain a collagen-binding domain within their catalytic domain, distinguishing them from other MMPs. A more detailed structure of these enzymes is described in a review by Björklund and Koivunen [10].
2. Activation of MMP-9

Typically, gelatinases are secreted as inactivezymogens that become activated extracellularly. The most relevant natural activators of proMMP-9 are unknown, but proMMP is activated through several different mechanisms, including proteolytic activation, where the prodomain is cleaved yielding an active enzyme. Latent MMP-9 can be activated by MMP-3, which cleaves proMMP-9 at multiple sites: the first cleavage site is Glu$^{59}$-Met$^{60}$; the second is Arg$^{106}$-Phe$^{107}$ [11]. In contrast, MMP-26 activates MMP-9 by cleaving at Ala$^{93}$-Met$^{94}$ [12]. Previous studies have also demonstrated that endotekinase, a membrane-bound serine protease, cleaves proMMP-9 at Lys$^{65}$-Ser$^{66}$ [13] and that trypsin-2 activates proMMP-9 at very low molar ratios, 1:1000. The peptide bond can also be cleaved at Arg$^{87}$-Phe$^{88}$ [14]. Other known proteolytic activators are plasmin, chymotrypsin-like proteinase, MMP-2, MMP-7, MMP-10, and MMP-13 [15–20]. There are other identified activation mechanisms for MMP-9: oxidation by reactive oxygen species, S-nitrosylation, and allosteric activation, which occurs when proMMP-9 is bound to either a gelatin or type IV collagen [21–23]. In an invasive tongue squamous cell carcinoma cell line (HSC-3), MMP-9 is colocalized with trypsin-2 in intracellular vesicles [13]. This intracellular activation may be an alternative activation mechanism for proMMPs in oral cancers. Similar intracellular vesicle transports for MMP-9 are also found in melanoma cells and in ovarian cancer ascites [24, 25]. In oral squamous cell carcinoma (OSCC), the activation level of MMP-9 may be associated with a shortened disease-free survival and a high metastatic frequency [26].

3. Inhibitors of MMP-9

Tissue inhibitors of metalloproteinases (TIMPs) are specific endogenous inhibitors of MMPs, which bind MMPs in a 1:1 stoichiometry. Four different TIMPs have been identified: TIMP-1, TIMP-2, TIMP-3, and TIMP-4 [27]; they all inhibit MMP-9 in vitro [28–31]. The role of TIMPs in OSCC is well-studied and is the focus of a recent review by García et al. [32]. After the role of MMPs in cancer invasion and metastasis formation was recognized, researchers began developing synthetic inhibitors. The first generation of peptidomimetic MMPs, batimastat (BB94) and ilomastat (GM-6001), mimicked the structure of collagen and reversibly bound the active site of MMPs to inhibit MMP activity [33, 34]. Next, Marimastat (BB-2516), a second generation of MMP inhibitors, was developed. However, all of these broad-spectrum inhibitors failed in clinical trials due to their side effects and their lack of efficacy [35–37], which led to the development of more selective matrix metalloproteinase inhibitors (MMPIs). We developed the first gelatinase-specific MMPI CTTHWGFTLC peptide, which inhibited the invasion of ovarian carcinoma, breast carcinoma, fibrosarcoma, Kaposi’s sarcoma, and melanoma cell lines, in vitro; it also increased the survival of human tumor xenografts [38]. Since then, we have developed a cyclic gelatinase-specific inhibitor GRENYHGCTTHWGFTLC peptide, which inhibits MMP-9 activation and activity, the growth of human tongue cancer xenografts, and angiogenesis in nude mice [39]. The synthetic MMPIs that inhibit MMP-9 are listed in Table 1.

4. MMP-9 in the Oral Microenvironment

In addition to carcinoma cells, cancers consist of tumor-associated stromal cells, which include fibroblasts, endothelial cells, leukocytes, macrophages, nerve cells, and adipocytes. During cancer progression, the cancer cells cross talk with stromal components and their interactions are partially mediated by transmembrane receptors, which are expressed on cancer cells and stromal cells. Tumor-associated cells promote angiogenesis, inflammation, invasion, and ECM
modeling through cell-cell contact and the production of growth factors, hormones, cytokines, and proteinases such as MMPs [56–58]. In OSCC tumors, MMP-9 is expressed in carcinoma and inflammatory cells around carcinoma islands. Meanwhile, MMP-2 is mainly found in carcinoma-associated fibroblasts (CAFs) [59, 60]. In an oral squamous cell carcinoma cell line SCC-25, CAFs increase the expression of MMP-9, in vitro, which is thought to occur via a fibronectin-integrin αvβ6 pathway [61]. In the aggressive human tongue squamous cell carcinoma cell line HSC-3, MMP-2 was only found in its latent form, whereas MMP-9 was found in its active form [13]. MMP-9 s effect during HSC-3 cell line invasion was studied in a human organotypic model based on myoma tissue [62], which contains fibroblasts, smooth muscle cells, lymphocytes, macrophages, endothelial cells, and MMP-2, but not MMP-9 [62]. Therefore, this model is a better predictor of the in vivo tumor microenvironment compared with the commonly used rat tail-derived type I collagen and/or the mouse EHS sarcoma-derived Matrigel invasion assay. In the myoma organotypic invasion assay, after inhibiting gelatinase activity in HSC-3 cells using a specific gelatinase inhibitor CTTHWGFTLC [38], the tumor cells were surprisingly more invasive than in the control group (unpublished data). Mice bearing HSC-3 xenograft tumors treated with the gelatinase inhibitor CTTHWGFTLC had smaller primary tumors in vivo than the control group [39], but the inhibition of gelatinases did not affect local invasion or metastasis formation [63]. The ability of cancer cells to change their migration under certain circumstances from proteolytic to non-proteolytic, amoeboid type during protease-inhibitor treatment helps to explain the OSCC behaviors we observed. Thus, these cells change their shape and adapt to squeeze through tissue gaps without degrading the ECM [64]. MMP-9 may not be the only, or even the most important, proteolytic enzyme in the OSCC invasion process, but it may be important for indirect cell signaling by controlling the bioavailability and bioactivity of molecules that target specific receptors, which regulate cell growth, migration, inflammation, and angiogenesis [65–69].

5. The Role of MMP-9 in OSCC Invasion and Metastasis

MMP-9 is associated with the aggressive nature of many cancers, including OSCC [81–84], and this aggressive nature was thought to cause type IV collagen degradation, a main component of basement membranes [85]. To date, the spectrum of MMP-9 matrix substrates has significantly increased, and aside from substrates, which originate in the matrix, MMP-9 has other bioactive substrates that independently modulate carcinogenesis, such as the pro-transforming growth factor-β1 (TGF-β1) and the pro-tumor necrosis factor-α (TNF-α) [10, 86, 87]. MMP-9 has traditionally been associated with the aggressive nature of OSCC. However, in spite of increased MMP-9 expression levels, many researchers have presented contradictory results [70–72] (Table 2). For example, Guttman et al. [73] did not find a correlation between MMP-9 expression and the size of the primary tumor or the neck metastasis in tongue SCC patients. Meanwhile, another study reported that high levels of MMP-9 expression in OSCC patients were correlated with regional lymph node and/or distant metastases and a poor prognosis [74]. In addition, De Vicente et al. [78] showed that MMP-9 expression was not associated with clinical variables, such as tumor stage or recurrence rate. In a study conducted by Ikebe et al., gelatinolytic activity and increased expression of both MMP-2 and MMP-9 in OSCC tumors were related to the invasiveness, but not to the metastatic potential of OSCC tumors [75]. Finally, Kato and co-workers [76] showed that, although MMP-9 expression was high in OSCCs, the activated form:proform ratio was very low, while activated MMP-2s were elevated and associated with advanced stages of disease. These findings suggest that MMP-9 may not be a universal cancer progression promotion factor in OSCCs; instead, it may have fluctuating roles.

6. MMP-9 in the Modulation of Cancer-Related Inflammation

Chronic inflammation is associated with epithelial cancers, and it differs from normal inflammation because it is not self-limiting. Cancer cells produce different cytokines that attract innate immune cells, such as mast cells, granulocytes, and macrophages. These innate immune cells then secrete interleukins, chemokines, reactive oxygen species, and MMPs that modulate angiogenesis, cell proliferation, tumor growth, and invasion [88–90]. In OSCCs, the level of a multifunctional cytokine, transforming growth factor-β1, is upregulated, which leads to the enhanced expression of snail. Snail is a transcription factor that increases MMP-9 expression and triggers an epithelial-mesenchymal transition (EMT); then, carcinoma cells change their morphology, reduce their intercellular and cell-matrix adhesions, and increase their motility [91, 92]. Interestingly, the inactive form of TGF-β1 is activated by MMP-9 [93]. Many other cytokines are also substrates for MMP-9, including TNF-α, CXCL1, CXCL4, CXCL7, CXCL8, and interleukin-1β [65–67]. Interleukin-1β is secreted by tumor cells and induces the expression of lipocalin 2 [94, 95]. The plasma levels of lipocalin 2, MMP-9 and the lipocalin 2/MMP-9 complex are associated with more advanced clinical stages and/or tumor sizes in OSCC patients. Interestingly, MMP-9 levels are not correlated with either lymph nodes or distant metastases [77]. Chemokine CXCL8 can induce the release of MMP-9 from tertiary neutrophil granules, and increased CXCL8 expression is associated with OSCC. The CXCL8 expressed in tumor cells is also secreted by OSCC cell lines, and CXCL8 mRNA expression is enhanced by the addition of TNF-α and IL-1β. CXCL8 from OSCC cell lines increases cell migration, induces invasion, and increases the expression of MMP-7. However, it does not have an effect on MMP-9 expression. Therefore, CXCL8-induced expression of MMP-9 may be cell-type specific [96–98]. The chemokine receptor, CXCR4, modulates the invasion of OSCCs by regulating MMP-9 expression. In patients, this expression correlates with lymph node metastasis and MMP-9 expression [99, 100]. Cyclooxygenase (COX)-2 is an enzyme that converts arachidonic
acid into pro-inflammatory prostanoids. COX-2 has been implicated in carcinogenesis and its mRNA expression is nearly 150-fold greater in head and neck squamous cell carcinomas compared with normal oral mucosa. Using a selective COX-2 inhibitor decreases MMP-9 and MMP-2 expression and suppresses the proliferation and invasion of OSCCs [101, 102]. In fact, MMP-9 has many links to the cancer-related inflammation observed in OSCCs, but MMP-9’s specific role in this process remains unclear.

7. MMP-9 in the Regulation of Angiogenesis

Low oxygen levels, or hypoxia, are typical in solid tumors that grow 1-2 mm³ without vascularization. Angiogenesis, the formation of new blood vessels, is required to bring nutrition and oxygen to cells, remove metabolic waste, and support larger tumor growth. Not only is angiogenesis associated with tumor growth, it is also related to the development of metastases in OSCCs [103–107]. This process is initiated by vascular endothelial growth factor (VEGF), an angiogenic cytokine. The effect of VEGF is mediated by vascular endothelial growth factor receptors. The hypoxic conditions stabilize hypoxia-inducible factors (HIFs) that bind to the VEGF promoter, which causes upregulation of VEGF and increases the expression of VEGFR-receptor-1 in endothelial cells, cancer cells and tumor-associated cells, such as macrophages [105, 108–111]. In OSCCs, overexpression of HIF-1α is associated with a poor patient outcome [112]. Increased tumor hypoxia is also associated with increased MMP-2 and MMP-9 activity [113].

The regulation of angiogenesis is a very delicate balance between pro- and antiangiogenic factors, and it seems that MMP-9 plays a dual role in this process. It can act as a proangiogenic factor via VEGF regulation; as Hiratsuka et al. [114] demonstrated, primary tumors in premetastatic lungs induce MMP-9 expression in a VEGFR-1-dependent manner, which enhances the invasion of cancer cells and facilitates metastasis. MMP-9 also triggers the angiogenic switch by releasing VEGF [87]. MMP-9 and VEGF are expressed during invasive OSCCs of the tongue and in metastatic tumors that tend to express higher levels of VEGF and MMP-9, than nonmetastatic tumors [115]. In another study, increased VEGF expression was associated with a poor prognosis in OSCC patients, whereas MMP-9 expression levels had no correlation with patient outcomes [116]. This can be explained by the antiangiogenic role of MMP-9, which causes cleavage of type XVIII collagen, and leads to the release of endostatin, a potent inhibitor of angiogenesis and endothelial cell migration [68, 69]. OSCC primary tumors that do not metastasize have high endostatin levels compared with primary tumors that are associated with multiple metastatic lymph nodes. Full-length collagen XVIII expression levels are decreased in aggressive tumors [117]. Based on our study [118], collagen XVIII was expressed in mild oral epithelial dysplasias but was absent in the invasive fronts of OSCCs. Although MMP-9 expression was observed in these same samples, there was no correlation between MMP-9 and the stage of disease. Homer et al. [119] reported that in head and neck squamous cell carcinoma, the plasma levels of endostatin may predict tumor recurrence. Collagen XVIII and VEGF are both expressed at the same time in OSCCs, which further demonstrates that modulation of angiogenesis requires a delicate balance between angiogenic inhibitors and stimulators [109]. Moreover, we have demonstrated that endostatin also directly inhibits the invasion and intravasation of a human tongue SCC cell line and blocks the activity of proMMP-9, suggesting a feedback loop for MMP-9 regulation [120]. When mice

### Table 2: MMP-9 expression in oral cancer.

| MMP-9 expression | Sample type | Lymph node metastasis | Outcome | MMP-9 activity | Method | Number of cases | References |
|------------------|-------------|-----------------------|---------|----------------|--------|-----------------|------------|
| High             | Tissue      | Yes                   | *       | Immunohistochemistry | 96     | [70]            |
| Yes              | Tissue      | Yes                   | *       | Immunohistochemistry | 61     | [71]            |
| High             | Tissue      | *                     | Shortened disease survival | Gelatin zymography, immunohistochemistry | 44     | [72]            |
| Yes              | Tissue      | No                    | nc      | Immunohistochemistry | 23     | [73]            |
| High             | Tissue      | Yes                   | Poor    | Immunohistochemistry | 53     | [74]            |
| High             | Tissue      | No                    | *       | Gelatin zymography, immunohistochemistry, western blot | 57     | [75]            |
| High             | Tissue      | *                     | *       | Low            | Immunohistochemistry, gelatin zymography, | 31     | [76]            |
| High             | Plasma      | No                    | *       | ELISA | 195 | [77]            |
| High             | Tissue      | No                    | nc      | Immunohistochemistry | 68     | [78]            |
| High             | Tissue      | *                     | Better survival | Immunohistochemistry | 12     | [79]            |
| High             | Tissue      | Yes                   | Shortened disease survival | Immunohistochemistry | 48     | [80]            |

* Not studied, nc: no correlation.
bearing nasopharyngeal carcinoma tumors were treated with endostar (recombinant endostatin), the treatment led to a significant decrease in MMP-9 and VEGF expression levels and normalized the tumor vasculature [121]. Endostatin was not the only cryptic angiogenesis inhibitor liberated by MMP-9. Angiostatin, a fragment of plasminogen, also inhibits endothelial cell proliferation [86, 122]. Pozzi et al. [123] proved that decreased MMP-9 plasma levels in tumor-bearing mice also decreases angiostatin levels, which increases tumor vascularization and growth. Matsumoto et al. [124] observed that angiostatin-overexpressing SCC tumors in mice grew slower than the control tumors. Aside from endostatin and angiostatin production, MMP-9 is also associated with the proteolytic degradation of type IV collagen, which produces an angiogenesis inhibitor, tumstatin [125, 126]. These findings suggest that in cancer angiogenesis the variations in spatial and temporal MMP-9 expression may switch between two roles: from a proangiogenic to an antiangiogenic molecule (Figure 1).

### 8. Effect of Genetic and Environmental Factors on the Expression of MMP-9

The development and progression of OSCCs are a result of interactions between accumulating genetic alterations and environmental factors, such as alcohol, tobacco, viral infection, or chronic inflammation [127]. Despite newer cancer treatments, approximately 50% of patients die within 5 years of diagnosis [128]. This can be partially explained by the theory of oral field cancerization: an oral mucosa exposed to carcinogens, such as alcohol, causes multiple genetic abnormalities in the entire epithelium and increases the risk of developing several dysplastic lesions [129]. Polymorphisms in the MMP9 gene allele are associated with an increased risk of developing the initial stages of oral cancer among patients without a family history of cancer and high smoking and/or alcohol use [130]. MMP-9 expression did not correlate with age, gender, tumor location, or smoking habits, whereas an association with tumor grade differentiation and alcohol consumption was observed [78]. MMP-9 was not expressed in the normal oral mucosa or dysplasia, whereas in situ carcinomas were weakly detectable. In OSCC, it was expressed in the same areas where collagen (IV) chain loss was observed at the invasive fronts, whereas in other studies, its overexpression was detected in 85% of oral dysplasias and in all of the oral cancer samples. The mRNA levels of MMP-9 were higher in oral dysplasia that progressed to OSCC [131, 132]. Ogbureke et al. 2012 [133] proposed that MMP-9 expression at histologically negative surgical margins could predict OSCC recurrence. Interestingly, MMP-9 was absent from the margins of tumors ≤4 cm and only 10% of tumors without later node metastasis expressed it. MMP-9 expression alternates between different stages of malignant transformations. Different clinicopathological variables in OSCCs can partially be explained by viral infections in epithelial cells. The human papilloma virus (HPV) is associated with OSCCs, especially type 16. HPV16 transgenic mice, HPV16/MMP-9 +/+ and HPV16/MMP-9 +/- develop a similar incidence of SCC after 12 months of age, whereas HPV16/MMP-9 −/− mice have fewer tumors, but these tumors were more poorly differentiated than those in the other groups. The expression of HPV16 oncoproteins in human keratinocytes induced the upregulation of MMP-9 activity. At the same time, two natural MMP inhibitors were downregulated. One of them was the reversion-inducing cysteine-rich protein with Kazal motifs (RECK), which affects transcription, synthesis, activation, and the activity of MMPs; the other was TIMP-2 [134–136]. HPV16 infection may be one mechanism behind the contradictory expression of MMP-9 in OSCC patients; however, further studies are necessary to understand its significance.

### 9. Methods for MMP-9 Investigation in Oral Cancer

The most commonly used immunohistological analyses of MMP-9 expression can be misleading because most antibodies do not distinguish between the pro- and active forms of the protein. The total amount of protein expression does not necessarily mean that the enzyme is in an active form [137]. Gelatin zymography or in situ zymography [138, 139] are better methods to evaluate the level of gelatinase activity...
and would have provided more information in the studies referred to here (Table 2) [139]. Many other techniques can investigate the presence, amount and function of MMP-9. For example, in situ hybridization could define the location and number of cells that express MMP-9 mRNA in tissue sections, whereas the polymerase chain reaction (PCR) could detect the presence and amount of mRNA in tissues or cell extracts [140, 141]. More specific intracellular localization of MMP-9 could easily be achieved using confocal laser scanning microscopy, which enables a 3-dimensional definition of protein localization [13]. Enzyme-linked immunosorbent assays (ELISAs) could be used to determine the concentration of MMP-9 protein in serum and plasma samples; based on these studies, MMP-9 is a systemic biomarker that monitors the effectiveness of OSCC treatment [112, 141, 142]. Different blotting methods, Western, Northern, and Southern, reveal the expression of protein, RNA or DNA, respectively, in various samples [75, 143]. MMPIs, transfected cell lines, and knock-out animal models give more functional data about MMP-9 [144, 145]. Most likely, the variety of methodologies and the low sample sizes explain the high variation observed among the previous OSCC results. Therefore, more studies with larger well-documented clinical materials, using delicate methods, are necessary to determine the impact of MMP-9 in OSCC.

10. Conclusions

Generally MMP-9 has been associated with aggressive head and neck cancers, but novel studies have shown that it acts as a protective molecule during carcinogenesis and metastasis. For example, in salivary gland myoepithelial carcinoma, MMP-9 expression predicts a better overall survival, and in regional metastases of head and neck cancers, MMP9 gene expression was decreased [79, 146]. Similarly, the expression of MMP-9 is associated with a better outcome in breast- and colitis-associated carcinomas [147, 148]. Additionally, in oral cancer the role of MMP-9 was purely associated with the degradation of the ECM, which led to the enhancement of carcinoma cell invasion. However, the philosophy of oral carcinoma progression has become significantly more complicated; now, MMP-9 is known as a multifunctional modulator that is involved in very complex cell-signaling cascades (Figure 2). Therefore, in the case of MMP-9, one reason for the obvious failures of broad-spectrum and specific MMPIs in cancer treatment might be due to its fluctuating role in cancer, which not only affects carcinoma cells but also other cell populations. The tumor microenvironment matrix expresses and sequesters MMP-9. Taken together, our current knowledge of MMP-9 has been extended; it can act as either a carcinoma protector or promoter depending on the specific situation, which is related to patient characteristics, including the stage, grade, and location of the tumor.

Acknowledgments

This study was supported by the Academy of Finland, Finnish Dental Society Apollonia, Finnish Cultural Foundation, Sigrid Juselius Foundation, Funds from the Helsinki and Oulu University Hospital state support for research (EVO and KEVO), and Helsinki Biomedical Graduate School.

References

[1] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011.
[2] P. E. Petersen, “Oral cancer prevention and control—the approach of the World Health Organization,” Oral Oncology, vol. 45, no. 4-5, pp. 454–460, 2009.
[3] H. Nagase, R. Visse, and G. Murphy, “Structure and function of matrix metalloproteinases and TIMPs,” Cardiovascular Research, vol. 69, no. 3, pp. 562–573, 2006.
[4] G. S. Butler and C. M. Overall, “Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics,” Biochemistry, vol. 48, no. 46, pp. 10830–10845, 2009.

[5] T. Klein and R. Bischoff, “Physiology and pathophysiology of matrix metalloproteinases,” Amino Acids, vol. 41, no. 2, pp. 271–290, 2011.

[6] G. Giannelli, J. Falk-Marzillier, O. Schiraldi, W. G. Stetler-Stevenson, and V. Quaranta, “Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5,” Science, vol. 277, no. 5323, pp. 225–228, 1997.

[7] M. D. Sternlicht and Z. Werb, “Control of matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001.

[8] M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nature Reviews Cancer, vol. 2, no. 3, pp. 161–174, 2002.

[9] E. Hadler-Olsen, B. Fadnes, I. Syle, L. Uhlin-Hansen, and J. O. Winberg, “Regulation of matrix metalloproteinase activity in health and disease,” FEBS Journal, vol. 278, no. 1, pp. 28–45, 2011.

[10] M. Björklund and E. Koivunen, “Gelatinase-mediated migration and invasion of cancer cells,” Biochimica et Biophysica Acta, vol. 1755, no. 1, pp. 37–69, 2005.

[11] Y. Ogata, J. J. Enghild, and H. Nagase, “Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9,” Journal of Biological Chemistry, vol. 267, no. 6, pp. 3581–3584, 1992.

[12] Y. G. Zhao, A. Z. Xiao, R. G. Newcomer et al., “Activation of progelatinase B by endomembrane/matrixin-2 promotes invasion of human prostate cancer cells,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 15056–15064, 2003.

[13] S. T. Vilen, P. Nyberg, M. Hukkanen et al., “Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma,” Experimental Cell Research, vol. 314, no. 4, pp. 914–926, 2008.

[14] T. Sorsa, T. Salo, E. Koivunen et al., “Activation of type IV procollagenases by human tumor-associated trypsin-2,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 21067–21074, 1997.

[15] R. Mazzieri, L. Masiero, L. Zanetta et al., “Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5,” Science, vol. 277, no. 5323, pp. 225–228, 1997.

[16] Y. P. Han, Y. D. Nien, and W. L. Garner, “Tumor necrosis factor-α-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase,” Journal of Biological Chemistry, vol. 277, no. 30, pp. 27319–27327, 2002.

[17] Y. G. Zhao, A. Z. Xiao, R. G. Newcomer et al., “Activation of progelatinase B by endomembrane/matrixin-2 promotes invasion of human prostate cancer cells,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 15056–15064, 2003.

[18] R. Fridman, M. Toth, D. Pena, and S. Mobashery, “Activation of progelatinase A (MMP-9) by gelatinase A (MMP-2),” Cancer Research, vol. 55, no. 12, pp. 2548–2555, 1995.

[19] D. C. Von Bredow, A. E. Cress, E. W. Howard, G. T. Bowden, and R. B. Nagle, “Activation of gelatinase-tissue-inhibitors of-metalloproteinase complexes by matrixin,” Biochemical Journal, vol. 331, no. 3, pp. 965–972, 1998.

[20] H. Nakamura, Y. Fujii, E. Ohuchi, E. Yamamoto, and Y. Okada, “Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases,” European Journal of Biochemistry, vol. 253, no. 1, pp. 67–75, 1998.

[21] V. Knäuper, B. Smith, C. López-Otin, and G. Murphy, “Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13),” European Journal of Biochemistry, vol. 248, no. 2, pp. 369–373, 1997.

[22] G. J. Peppin and S. J. Weiss, “Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 12, pp. 4322–4326, 1986.

[23] Z. Gu, M. Kaul, B. Yan et al., “S-nitrosylation of metalloproteinases: signaling pathway to neuronal cell death,” Science, vol. 297, no. 5584, pp. 1186–1190, 2002.

[24] G. A. Bannikov, T. V. Karelina, I. E. Collier, B. L. Marmer, and G. I. Goldberg, “Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 16022–16027, 2002.

[25] L. E. Graves, E. V. Ariztia, J. R. Navari, H. J. Matzel, M. S. Stack, and D. A. Fishman, “Proinvasive properties of ovarian cancer ascites-derived membrane vesicles,” Cancer Research, vol. 64, no. 19, pp. 7045–7049, 2004.

[26] E. M. Schnaeker, R. Ossig, T. Ludwig et al., “Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion,” Cancer Research, vol. 64, no. 24, pp. 8924–8931, 2004.

[27] S. D. Hong, S. P. Hong, J. I. Lee, and C. Y. Lim, “Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential,” Oral Oncology, vol. 36, no. 2, pp. 207–213, 2000.

[28] K. Brew and H. Nagase, “The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity,” Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 55–71, 2010.

[29] E. C. Bullen, M. J. Banda, and S. J. Weiss, “Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2,” Journal of Biological Chemistry, vol. 266, no. 20, pp. 13070–13075, 1991.

[30] J. P. O’Connell, E. Willenbrock, A. J. P. Docherty, D. Eaton, and G. Murphy, “Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B,” Journal of Biological Chemistry, vol. 269, no. 21, pp. 14967–14973, 1994.

[31] G. S. Butler, S. S. Apte, E. Willenbrock, and G. Murphy, “Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B: regulation by polyanions,” Journal of Biological Chemistry, vol. 274, no. 16, pp. 10846–10851, 1999.

[32] Y. E. Liu, M. Wang, J. Greene et al., “Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4),” Journal of Biological Chemistry, vol. 272, no. 33, pp. 20479–20483, 1997.

[33] M. P. S. Garcia, J. M. Suárez-Peñaranda, P. Gayoso-Diz, F. Barros-Angueira, J. M. Gándara-Rey, and A. García-García, “Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas—a therapeutic target?” Cancer Letters, vol. 323, no. 1, pp. 11–19, 2012.

[34] P. D. Brown, “Matrix metalloproteinase inhibitors,” Breast Cancer Research and Treatment, vol. 52, no. 1-3, pp. 125–136, 1998.

[35] C. M. Overall and O. Kleifeld, “Towards third generation matrix metalloproteinase inhibitors for cancer therapy,” British Journal of Cancer, vol. 94, no. 7, pp. 941–946, 2006.
[35] S. M. Wojtowicz-Praga, R. B. Dickson, and M. J. Hawkins, "Matrix metalloproteinase inhibitors," Investigational New Drugs, vol. 15, no. 1, pp. 61–75, 1997.

[36] S. Zucker, J. Cao, and W. T. Chen, "Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment," Oncogene, vol. 19, no. 56, pp. 6642–6650, 2000.

[37] L. M. Coussens, B. Fingleton, and L. M. Matrisian, "Matrix metalloproteinase inhibitors and cancer: trials and tribulations," Science, vol. 295, no. 5564, pp. 2387–2392, 2002.

[38] T. A. Sutton, K. J. Kelly, H. E. Mang, Z. Plotkin, R. M. Sandoval, and P. C. Dagher, "Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury," American Journal of Physiology, vol. 288, no. 1, pp. F191–F197, 2005.

[39] D. R. Shalinsky, J. Brekken, H. Zou et al., "A phase III randomized trial of BAY 12-9566 (tannomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study," Gynecologic Oncology, vol. 102, no. 2, pp. 300–308, 2006.

[40] H. Hirte, I. B. Vergote, J. R. Jeffrey et al., "An inhibition of angio genesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291," Cancer Research, vol. 61, no. 23, pp. 8480–8485, 2001.

[41] T. Sorsa, N. S. Ramamurthy, A. T. Vernillo et al., "Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases," Journal of Rheumatology, vol. 25, no. 5, pp. 975–982, 1998.

[42] Z. Gu, J. Cui, S. Brown et al., "A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia," Journal of Neuroscience, vol. 25, no. 27, pp. 6401–6408, 2005.

[43] P. C. Dagher, "Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury," American Journal of Physiology, vol. 288, no. 1, pp. F191–F197, 2005.

[44] D. R. Shalinsky, J. Brekken, H. Zou et al., "A phase III randomized trial of BAY 12-9566 (tannomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study," Gynecologic Oncology, vol. 102, no. 2, pp. 300–308, 2006.

[45] R. Gendron, D. Grenier, T. Sorsa, and D. Mayrand, "Inhibition of matrix metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells," International Journal of Cancer, vol. 104, no. 2, pp. 155–160, 2003.

[46] Z. Gu, J. Cui, S. Brown et al., "A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia," Journal of Neuroscience, vol. 25, no. 27, pp. 6401–6408, 2005.

[47] P. C. Dagher, "Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury," American Journal of Physiology, vol. 288, no. 1, pp. F191–F197, 2005.

[48] D. R. Shalinsky, J. Brekken, H. Zou et al., "A phase III randomized trial of BAY 12-9566 (tannomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study," Gynecologic Oncology, vol. 102, no. 2, pp. 300–308, 2006.

[49] R. Gendron, D. Grenier, T. Sorsa, and D. Mayrand, "Inhibition of matrix metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells," International Journal of Cancer, vol. 104, no. 2, pp. 155–160, 2003.

[50] O. Teronen, M. Laitinen, T. Salo et al., "Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma," Blood, vol. 96, no. 12, pp. 4006–4007, 2000.

[51] Z. Gu, J. Cui, S. Brown et al., "A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia," Journal of Neuroscience, vol. 25, no. 27, pp. 6401–6408, 2005.

[52] P. C. Dagher, "Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury," American Journal of Physiology, vol. 288, no. 1, pp. F191–F197, 2005.

[53] D. R. Shalinsky, J. Brekken, H. Zou et al., "A phase III randomized trial of BAY 12-9566 (tannomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study," Gynecologic Oncology, vol. 102, no. 2, pp. 300–308, 2006.
blocking of pericellular proteolysis,” *Journal of Cell Biology*, vol. 160, no. 2, pp. 267–277, 2003.

[65] A. J. H. Gearing, P. Beckett, M. Christodoulou et al., “Matrix metalloproteinases and processing of pro-TNF-α,” *Journal of Leukocyte Biology*, vol. 57, no. 5, pp. 774–777, 1995.

[66] A. Ito, A. Mukaiyama, Y. Itoh et al., “Degradation of interleukin 1β by matrix metalloproteinases,” *Journal of Biological Chemistry*, vol. 271, no. 25, pp. 14657–14660, 1996.

[67] P. E. Van Den Steen, P. Proost, A. Wuyts, J. Van Damme, and G. Opdenakker, “Neutrophil gelatinase B potentiates interleukin-8 tenfold by amniontinal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact,” *Blood*, vol. 96, no. 8, pp. 2673–2681, 2000.

[68] M. Ferreras, U. Felbor, T. Lenhard, B. R. Olsen, and J. M. Delaissé, “Generation and degradation of human endostatin proteins by various proteinases,” *FEBS Letters*, vol. 486, no. 3, pp. 247–251, 2000.

[69] R. Heljasvaara, P. Nyberg, J. Luostarinen et al., “Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteinases,” *Experimental Cell Research*, vol. 307, no. 2, pp. 292–304, 2005.

[70] S.-I. Kurahara, M. Shinohara, T. Ikebe et al., “Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis,” *Head and Neck*, vol. 21, no. 7, pp. 627–638, 1999.

[71] C. X. Zhou, Y. Gao, N. W. Johnson, and J. Gao, “Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue,” *Australian Dental Journal*, vol. 55, no. 4, pp. 385–389, 2010.

[72] C. W. Yorioka, R. D. Coletta, F. Alves, I. N. Nishimoto, L. P. Kowalski, and E. Graner, “Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients,” *International Journal of Oncology*, vol. 20, no. 1, pp. 189–194, 2002.

[73] D. Guttman, Y. Stern, T. Shpitzer, D. Ulanovski, T. Druzd, and I. Delaissé, “Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients,” *International Journal of Oncology*, vol. 20, no. 1, pp. 189–194, 2002.

[74] A. Katayama, N. Bandoh, K. Kishibe et al., “Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis,” *Clinical Cancer Research*, vol. 10, no. 2, pp. 634–640, 2004.

[75] T. Ikebe, M. Shinohara, H. Takcuchi et al., “Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer,” *Clinical and Experimental Metastasis*, vol. 17, no. 4, pp. 315–323, 1999.

[76] K. Kato, A. Hara, T. Kuno et al., “Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity,” *Journal of Cancer Research and Clinical Oncology*, vol. 131, no. 6, pp. 340–346, 2005.

[77] C.-W. Lin, S.-W. Tseng, S.-F. Yang et al., “Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer,” *Oral Diseases*, vol. 18, no. 8, pp. 734–740, 2012.

[78] J. C. De Vicente, M. F. Fresno, L. Villalain, J. A. Vega, and G. Hernández Valdejo, “Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma,” *Oral Oncology*, vol. 41, no. 3, pp. 283–293, 2005.

[79] A. Stokes, J. Joutsa, R. Ala-aho et al., “Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma,” *Clinical Cancer Research*, vol. 16, no. 7, pp. 2022–2035, 2010.

[80] H.-X. Fan, H.-X. Li, Z.-X. Gao, and J.-H. Zheng, “Changes in the expression of MMP2, MMP9, and CollIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications,” *Journal of Experimental and Clinical Cancer Research*, vol. 31, no. 1, article 90, 2012.

[81] M. Siewko, B. Mroczko, and M. Szmikowski, “The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer,” *Folia Histochemica et Cytobiologica*, vol. 50, no. 1, pp. 12–19, 2012.

[82] X. Hu, D. Li, W. Zhang, J. Zhou, and B. Tang, “Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion,” *Archives of Gynecology and Obstetrics*, vol. 26, 2012.

[83] Q. W. Zhang, L. Liu, and R. Chen, “Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis,” *Asian Pacific Journal of Cancer Prevention*, vol. 13, no. 6, pp. 2903–2908, 2012.

[84] H. Ruokolainen, P. Pääkkö, and T. Turpeenniemi-Hujanen, “Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker,” *International Journal of Cancer*, vol. 116, no. 3, pp. 422–427, 2005.

[85] W. G. Stetler-Stevenson, S. Azaavoorian, and L. A. Liotta, “Tumor cell interactions with the extracellular matrix during invasion and metastasis,” *Annual Review of Cell Biology*, vol. 9, pp. 541–573, 1993.

[86] B. C. Patterson and Q. A. Sang, “Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP9),” *Journal of Biological Chemistry*, vol. 272, no. 46, pp. 28823–28825, 1997.

[87] G. Bergers, R. Brekken, G. McMahon et al., “Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis,” *Nature Cell Biology*, vol. 2, no. 10, pp. 737–744, 2000.

[88] A. Mantovani, “Cancer: inflammation by remote control,” *Nature*, vol. 435, no. 7043, pp. 752–753, 2005.

[89] B. B. Aggarwal, S. Shishodia, S. K. Sandur, M. K. Pandey, and G. Sethi, “Inflammation and cancer: how hot is the link?” *Biochemical Pharmacology*, vol. 72, no. 11, pp. 1605–1621, 2006.

[90] D. Ribatti and E. Crivellato, “Mast cells, angiogenesis, and tumour growth,” *Biochimica et Biophysica Acta*, vol. 1822, no. 1, pp. 2–8, 2012.

[91] L. Sun, M. E. Diamond, A. J. Ottaviano, M. J. Joseph, V. Ananthanarayan, and H. G. Munshi, “Transforming growth factor-β1 promotes matrix metalloproteinase-9-mediated oral cancer invasion through snail expression,” *Molecular Cancer Research*, vol. 6, no. 1, pp. 10–20, 2008.

[92] S. Takayama, M. Hatori, Y. Kurihara, Y. Kinugasa, T. Shirota, and S. Shintai, “Inhibition of TGF-β1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases,” *Oncology Reports*, vol. 21, no. 1, pp. 205–210, 2009.

[93] Q. Yu and I. Stamenkovic, “Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis,” *Genes and Development*, vol. 14, no. 2, pp. 163–176, 2000.

[94] K. Shchors and G. Evan, “Tumor angiogenesis: cause or consequence of cancer?” *Cancer Research*, vol. 67, no. 15, pp. 7059–7061, 2007.
[126] Y. Maeshima, M. Manfredi, C. Reimerli et al., “Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin,” *Journal of Biological Chemistry*, vol. 276, no. 18, pp. 15240–15248, 2001.

[127] S. Choi and J. N. Myers, “Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy,” *Journal of Dental Research*, vol. 87, no. 1, pp. 14–32, 2008.

[128] D. M. Walker, G. Boey, and L. A. McDonald, “The pathology of oral cancer,” *Pathology*, vol. 35, no. 5, pp. 376–383, 2003.

[129] M. G. C. T. Van Oijen and P. J. Slootweg, “Oral field carcinogenesis: carcinogen-induced independent events or micrometastatic deposits?” *Cancer Epidemiology Biomarkers and Prevention*, vol. 9, no. 3, pp. 249–256, 2000.

[130] E. Vairaktaris, S. Vassiliou, E. Nkenke et al., “A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma,” *European Journal of Surgical Oncology*, vol. 34, no. 4, pp. 450–455, 2008.

[131] R. Tamamura, H. Nagatsuika, C. H. Siar et al., “Comparative analysis of basal lamina type IV collagenalpha chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma,” *Acta Histochemica*. In press.

[132] R. C. K. Jordan, M. Macabeo-Ong, C. H. Shiboski et al., “Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer,” *Clinical Cancer Research*, vol. 10, no. 9, pp. 6460–6465, 2004.

[133] K. U. Ogbureke, P. M. Weinberger, S. W. Looney et al., “Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma,” *Oncotarget*, vol. 3, no. 3, pp. 286–298, 2012.

[134] L. M. Coussens, C. L. Tinkle, D. Hanahan, and Z. Werb, “MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis,” *Cell*, vol. 103, no. 3, pp. 481–490, 2000.

[135] T. Ramqvist and T. Dalianis, “Oropharyngeal cancer epidemic and human papillomavirus,” *Emerging Infectious Diseases*, vol. 16, no. 11, pp. 1671–1677, 2010.

[136] M. A. Andreoli, C. di Loreto, A. L. Filho, L. L. Villa, and S. S. Maria-Engler, “HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis,” *PLoS ONE*, vol. 7, no. 3, Article ID e33585, 2012.

[137] S.-T. Vilen, J. Suojanen, F. Salas et al., “Trypsin-2 enhances carcinoma invasion by processing tight junctions and activating promt1-mmp,” *Cancer Investigation*, vol. 30, no. 8, pp. 583–592, 2012.

[138] E. Pirilä, P. Maisi, T. Salo, E. Koivunen, and T. Sorsa, “In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor,” *Biochemical and Biophysical Research Communications*, vol. 287, no. 3, pp. 766–774, 2001.

[139] P. A. M. Snoek-van Beurden and J. W. Von Den Hoff, “Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors,” *BioTechniques*, vol. 38, no. 1, pp. 73–83, 2005.

[140] L. Jin and R. V. Lloyd, “In situ hybridization: methods and applications,” *Journal of Clinical Laboratory Analysis*, vol. 11, no. 1, pp. 2–9, 1997.

[141] R. D. Singh, N. Haridas, J. B. Patel et al., “Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer,” *Indian Journal of Clinical Biochemistry*, vol. 25, no. 3, pp. 250–259, 2010.

[142] B. P. Patel, S. V. Shah, S. N. Shukla, P. M. Shah, and P. S. Patel, “Clinical significance of MMP-2 and MMP-9 in patients with oral cancer,” *Head and Neck*, vol. 29, no. 6, pp. 564–572, 2007.

[143] J. M. Berg, J. L. Tymoczko, and L. Stryer, *Biochemistry*, W.H. Freeman, New York, NY, USA, 5th edition, 2002.

[144] J. Suojanen, T. Salo, E. Koivunen, T. Sorsa, and E. Pirilä, “A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth,” *Cancer Biology and Therapy*, vol. 8, no. 24, pp. 2362–2370, 2009.

[145] K. Hotary, X. Y. Li, E. Allen, S. L. Stevens, and S. J. Weiss, “A cancer cell metalloproteinase triad regulates the basement membrane transmigration program,” *Genes and Development*, vol. 20, no. 19, pp. 2673–2686, 2006.

[146] H. Luukkaa, P. Klemi, I. Leivo et al., “Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer,” *Head and Neck*, vol. 32, no. 8, pp. 1019–1027, 2010.

[147] C. Bendrik, J. Robertson, J. Gauldie, and C. Dabrosin, “Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo,” *Cancer Research*, vol. 68, no. 9, pp. 3405–3412, 2008.

[148] P. Garg, D. Sarma, S. Jeppsson et al., “Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer,” *Cancer Research*, vol. 70, no. 2, pp. 792–801, 2010.